Skip to main content

Repare Therapeutics (RPTX) Receives a Buy from TD Cowen

Tipranks - Tipranks - Sat Aug 9, 2025

TD Cowen analyst Marc Frahm maintained a Buy rating on Repare Therapeutics today. The company’s shares opened today at $1.56.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Agios Pharma, and Scholar Rock Holding. According to TipRanks, Frahm has an average return of 6.0% and a 42.90% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Repare Therapeutics.

See today’s best-performing stocks on TipRanks >>

Based on Repare Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.04 million. In comparison, last year the company earned a revenue of $52.4 million and had a net profit of $13.16 million

Read More on RPTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).